India, Sept. 16 -- Alkem Laboratories announced the launch of NeuCeno (cenobamate), anti-seizure medication (ASM) for the treatment of partial-onset seizures in adult patients.Cenobamate, being launched for the first time in India, represents a significant advancement in the management of epilepsy. NeuCeno is a once daily oral therapy, and is available in 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg and 200 mg tablets.Epilepsy is a significant healthcare burden in India, with an estimated 9.4 million people living with the condition. Despite the availability of multiple anti-seizure medications, a significant proportion of patients continue to experience uncontrolled seizures, substantially affecting their independence, daily functioning and overa...